Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase. / Frederiksen, Kristian S; Hasselbalch, Steen; Law, Ian; Højgaard, Liselotte; Waldemar, Gunhild.

In: Ugeskrift for Laeger, Vol. 177, No. 24, V12140684, 08.06.2015.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Frederiksen, KS, Hasselbalch, S, Law, I, Højgaard, L & Waldemar, G 2015, 'Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase', Ugeskrift for Laeger, vol. 177, no. 24, V12140684.

APA

Frederiksen, K. S., Hasselbalch, S., Law, I., Højgaard, L., & Waldemar, G. (2015). Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase. Ugeskrift for Laeger, 177(24), [V12140684].

Vancouver

Frederiksen KS, Hasselbalch S, Law I, Højgaard L, Waldemar G. Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase. Ugeskrift for Laeger. 2015 Jun 8;177(24). V12140684.

Author

Frederiksen, Kristian S ; Hasselbalch, Steen ; Law, Ian ; Højgaard, Liselotte ; Waldemar, Gunhild. / Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase. In: Ugeskrift for Laeger. 2015 ; Vol. 177, No. 24.

Bibtex

@article{9de34bde479c49288265f4e717d4dc71,
title = "Biomark{\o}rer ved diagnostik af Alzheimers sygdom i tidlig fase",
abstract = "Alzheimer's disease is responsible for 40-50{\%} of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.",
author = "Frederiksen, {Kristian S} and Steen Hasselbalch and Ian Law and Liselotte H{\o}jgaard and Gunhild Waldemar",
year = "2015",
month = "6",
day = "8",
language = "Dansk",
volume = "177",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "24",

}

RIS

TY - JOUR

T1 - Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase

AU - Frederiksen, Kristian S

AU - Hasselbalch, Steen

AU - Law, Ian

AU - Højgaard, Liselotte

AU - Waldemar, Gunhild

PY - 2015/6/8

Y1 - 2015/6/8

N2 - Alzheimer's disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.

AB - Alzheimer's disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.

M3 - Tidsskriftartikel

VL - 177

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 24

M1 - V12140684

ER -

ID: 161949277